Comparative efficacy and safety of etoposide plus PEG-rhG-CSF versus etoposide plus G-CSF for haematopoietic stem cell mobilisation in patients with multiple myeloma and lymphoma
Frontiers in Oncology · 17.06.2026 · 16
DOI: 10.3389/fonc.2026.1879386 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 17.06.2026. Verfasst von Yiming Zhao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei, China. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Mobilisation
Abstract (Originalsprache)
Introduction
Efficient and safe mobilisation of haematopoietic stem cells is essential for successful autologous haematopoietic stem cell transplantation (ASCT). Although pegylated recombinant human granulocyte colony stimulating factor, (PEG-rhG-CSF) is widely used for chemotherapy-induced neutropenia, comparative data on its use with high-dose etoposide (VP-16) for mobilisation remain scarce. In particular, direct comparisons between mecapegfilgrastim and recombinant human G-CSF (rhG-CSF) in this setting are lacking.
Methods
In this retrospective study, we analysed the efficacy and safety of high-dose VP-16 (1.6 g/m 2 ) combined with PEG-rhG-CSF (100 μg/kg) versus high-dose VP-16 (1.6 g/m 2 ) combined with rhG-CSF (10 μg/kg/d) for stem cell mobilisation.
Results
Seventy-one patients were included: 32 received VP-16+PEG-rhG-CSF and 39 received VP-16+rhG-CSF. Baseline characteristics were comparable. Mobilisation success exceeded 90% in both groups. However, the PEG-rhG-CSF group achieved a significantly higher total CD34 + cell yield, a greater proportion of optimal mobilisers, and a higher first-day collection success rate. Fewer number of apheresis and a shorter mobilisation duration were observed in this group. The incidence of febrile infection was significantly lower with PEG-rhG-CSF, whereas platelet transfusion requirements and engraftment kinetics were similar between groups.
Conclusions
High-dose VP-16 combined with PEG-rhG-CSF demonstrated superior efficacy, safety, and procedural efficiency compared with high-dose VP-16 plus rhG-CSF. These findings suggest that this regimen represents a promising and potentially preferable alternative for haematopoietic stem cell mobilisation in patients with multiple myeloma or lymphoma.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
- Department of Hematology, Anhui Public Health Clinical Center, Hefei, China.
Zitieren
APA
Zhao, Y., Liu, L., Qian, W., Li, J., & Xia, L. (2026). Comparative efficacy and safety of etoposide plus PEG-rhG-CSF versus etoposide plus G-CSF for haematopoietic stem cell mobilisation in patients with multiple myeloma and lymphoma. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1879386
Vancouver
Zhao Y, Liu L, Qian W, Li J, Xia L. Comparative efficacy and safety of etoposide plus PEG-rhG-CSF versus etoposide plus G-CSF for haematopoietic stem cell mobilisation in patients with multiple myeloma and lymphoma. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1879386
BibTeX
@article{Zhao2026,
author = {Zhao, Yiming and Liu, Lixia and Qian, Wei and Li, Jianjun and Xia, Liang},
title = {Comparative efficacy and safety of etoposide plus PEG-rhG-CSF versus etoposide plus G-CSF for haematopoietic stem cell mobilisation in patients with multiple myeloma and lymphoma},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1879386}
}
EUVIMED